The attractiveness of CTLA-4 as a target has been fueled by the development of two fully human monoclonal antibodies, tremelimumab and ipilimumab, which have gained FDA approval and have been incorporated into clinical guidelines for the treatment of advanced melanoma [64]. Here, CTLA4 is linked to melanoma.